U.S. markets closed

Adial Pharmaceuticals, Inc. (ADIL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0200-0.0300 (-1.46%)
At close: 4:00PM EDT

2.0100 -0.01 (-0.50%)
After hours: 5:01PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close2.0500
Bid2.0400 x 900
Ask2.2000 x 1400
Day's Range2.0200 - 2.1171
52 Week Range1.1400 - 4.0000
Avg. Volume627,229
Market Cap34.885M
Beta (5Y Monthly)0.67
PE Ratio (TTM)N/A
EPS (TTM)-0.8740
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Adial Pharma Seeks To Treat The Pandemic Of Addiction

    Adial Pharma Seeks To Treat The Pandemic Of Addiction

    As COVID vaccines spread globally, many are returning to pre-pandemic life with routine and socialization. But what about the other pandemics? The problems of mental health and drug addiction have been prevalent in our society long before the coronavirus but were gravely exacerbated over the past year to the point that they might be called a “second pandemic.” The economic struggle combined with losing loved ones, healthcare, career opportunities, shelter, other disruptions to quality of life have caused some to turn to drugs and alcohol for comfort or an escape. Those who were previously addicts are no doubt struggling, but more and more names get added to the list daily. It’s been predicted that alcohol use increased globally by 75% over the past 12 months. So how does our society tackle this pandemic of Addiction? Adial Pharmaceuticals has one strategy. An Older Pandemic Alcohol use disorder (AUD) is known as the No. 1 cause of death to people considered to be in their prime. Aside from the many personal burdens that AUD puts on individuals and their families, the economic and global burdens are just as heavy. According to the American Journal of Preventive Medicine, in 2010, alcohol misuse cost the United States $249 billion — 77% of which is due to heavy and binge drinking days. And the World Health Organization reported in 2016 that 3 million deaths or 5.3% of all global deaths (7.7% for men and 2.6% for women) were attributable to alcohol consumption — 13.5% of all deaths for ages 20-39. Adial Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the treatment and prevention of addictions, is currently in Phase 3 testing of its lead investigational drug product called AD04. The company developed AD04 as a genetically-targeted therapeutic agent for the treatment of AUD. Phase 2b Results A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing the frequency and quantity of drinking and heavy drinking with no overt safety concerns. During the trial, ondansetron, the active pharmaceutical agent in AD04, showed a statistically significant difference in contrast with the placebo for both the primary endpoint and secondary endpoint, which were the reduction in the severity of drinking measured in drinks per day and the reduction in the frequency of drinking measured in days of abstinence/no drinking. Additionally, and importantly, the Phase 2b results showed a significant decrease in the percentage of heavy drinking days. “Heavy drinking days” were defined as any day with four or more alcoholic drinks for women or five or more alcoholic drinks for men consumed within the same day and are well-documented as the days that cause damage due to alcohol. How AD04 Would Work Unlike other therapies, Adial’s investigational product, AD04, involves genetic screening with a companion diagnostic genetic test prior to treatment and uses a novel mode of action that is designed to reduce cravings for alcohol to effectively curb alcohol intake, without the requirement of abstinence prior to or during treatment. It is expected to help people reduce their drinking or maintain abstinence. AD04 is intended to be easy to use; administered orally on a twice-daily basis, with a once-a-day tablet planned for the future. Adial’s strategy is to integrate pretreatment genetic screening with a test distributed to prescribers into AD04’s label to create a patient-specific treatment in one integrated therapeutic offering. The company’s goal is to develop a genetically targeted, effective and safe product candidate to treat AUD to help people live healthier and more fulfilling lives. According to the FDA, Adial’s AD04 is the only drug addressing AUD in this breakthrough method that has reached Phase 3 testing. Visit adialpharma.com to stay updated for more information, or follow the company on Twitter, LinkedIn and Facebook @AdialPharma or CEO Bill Stilley @BillStilley on Twitter and @WilliamStilley on LinkedIn. See more from BenzingaClick here for options trades from BenzingaKhiron Sets A Milestone As First Colombian Medical Cannabis Company To Export To EuropeVolition's Nu.Q® Provides Accurate, Non-Invasive Testing For Cancer Diagnosis In Humans And Canines© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Adial Pharmaceuticals to Participate at the Benzinga Biotech Small Cap Conference on March 24th

    Adial Pharmaceuticals to Participate at the Benzinga Biotech Small Cap Conference on March 24th

    Charlottesville, Virginia--(Newsfile Corp. - March 23, 2021) - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (NASDAQ: ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals will be presenting at the Benzinga Biotech Small Cap Conference at 1:40 pm EST on Wednesday, March 24, 2021. The Benzinga Biotech Small Cap Conference will be taking place from March 24-25, 2021.Investors interested in joining ...

  • Adial Founder and Chief Medical Officer Dr. Bankole Johnson Featured Guest on The Black News Channel

    Adial Founder and Chief Medical Officer Dr. Bankole Johnson Featured Guest on The Black News Channel

    Discusses long-term effects of COVID-19 pandemic on mental health and addictionCHARLOTTESVILLE, Va., March 17, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced Dr. Bankole Johnson, founder and Chief Medical Officer of Adial, was honored to be a guest on The Black News Channel (BNC). During the interview, he offered insights into the long-term effects of the COVID-19 pandemic on mental health and addiction. Dr. Johnson may serve as a featured guest on BNC in future interviews to discuss related topics. A replay of the interview is available on the media section of the Company’s website at: https://www.adialpharma.com/newsroom/media/. About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity, and the Company develops adenosine analogs for the treatment of pain and other disorders. Additional information is available at www.adialpharma.com. Forward Looking Statements This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to enroll patients within the timelines anticipated and complete clinical trials on time and achieve desired results and benefits as expected, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2019, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law. Contact:Crescendo Communications, LLC David Waldman / Natalya Rudman Tel: 212-671-1021 Email: adil@crescendo-ir.com